EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Enhanced Clearance of HIV ‐1 Broadly Neutralizing Antibody VRC07 ‐523‐ LS During Viremia: Influences on Trial Design and Analysis

Nicholas M Smith iD, Brian M Ho iD, Katharine J Bar iD, Lucio Gama, Gabrielle Dziubla iD, Richard A Koup iD, Michael Pensiero, Leonid Serebryannyy iD, Marina Caskey iD, Timothy J Wilkin iD, Troy D Wood, Gene D Morse iD und 3 weitere

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70488 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Nicholas M Smith und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of N…. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Broadly Neutralizing Antibodies, HIV Antibodies, HIV Infections. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Broadly neutralizing antibodies (BNAb) are capable of neutralizing multiple HIV‐1 strains through the targeting of conserved epitopes. This study's objective was to quantify the pharmacokinetic (PK) parameters describing the distribution and elimination of the BNAb VRC07‐523‐LS in people with HIV (PWH), and to identify the influence of viral load on VRC07‐523‐LS elimination. The PK of VRC07‐523‐LS was assessed in participants with and without HIV after intravenous or subcutaneous administration. A Bayesian strategy was utilized to estimate VRC07‐523‐LS PK parameters, leveraging a previously published study in adults without HIV. The effects of static viral loads on VRC07‐523‐LS exposure and time to a target trough serum concentration of 1 mg/L was then evaluated using clinical trial simulations. VRC07‐523‐LS serum concentrations were described by a two‐compartment model with first order absorption from the subcutaneous site. Typical clearance was estimated as 99.3 mL/day, which increased to a maximum of 6.46‐fold higher with viremia. Clinical trial simulations without viremia showed that a 700–2100 mg dose of VRC07‐523‐LS is expected to remain above the IC 50 of 0.055 mg/L beyond 52 weeks. With a viral load of 30,000 copies/mL, a 2100 mg dose of VRC07‐523‐LS is expected to result in 90% of participants having a concentration below 1 mg/L by 18.6 weeks, a decrease of 42 weeks compared to aviremic patients. Mechanistic modeling offers the ability to identify HIV viral load effects on BNAb PK and can improve BNAb dosing, especially with consideration of acute versus maintenance treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingBroadly Neutralizing AntibodiesHIV AntibodiesHIV InfectionsHIV-1ViremiaAdultFemaleHumansMaleMiddle AgedAdministration, IntravenousBayes TheoremInjections, SubcutaneousResearch DesignViral Load

Stichwörter der Autor:innen

BayesianHIV‐1adaptive clinical trialbroadly neutralizing monoclonal antibodiesgenetic algorithmmachine learningmonoclonal antibodypopulation pharmacokinetics

Substanzen

Antibodies, NeutralizingBroadly Neutralizing AntibodiesHIV Antibodies

Autor:innen und Institutionen

  • Division of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York, USA.
  • Department of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
  • Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
  • University of California, San Diego, La Jolla, California, USA.

ORCID-Profile: Nicholas M Smith, Brian M Ho, Katharine J Bar, Gabrielle Dziubla, Richard A Koup, Leonid Serebryannyy, Marina Caskey, Timothy J Wilkin, Gene D Morse, Charles S Venuto, Ray Cha

Förderung

  • NIAID NIH HHS

Zitieren

APA

Smith, N. M., Ho, B. M., Bar, K. J., Gama, L., Dziubla, G., Koup, R. A., Pensiero, M., Serebryannyy, L., Caskey, M., Wilkin, T. J., Wood, T. D., Morse, G. D., Venuto, C. S., Cha, R., & Ma, Q. (2026). Enhanced Clearance of HIV ‐1 Broadly Neutralizing Antibody VRC07 ‐523‐ LS During Viremia: Influences on Trial Design and Analysis. Clinical and Translational Science. https://doi.org/10.1111/cts.70488

Vancouver

Smith NM, Ho BM, Bar KJ, Gama L, Dziubla G, Koup RA, et al. Enhanced Clearance of HIV ‐1 Broadly Neutralizing Antibody VRC07 ‐523‐ LS During Viremia: Influences on Trial Design and Analysis. Clinical and Translational Science. 2026. doi:10.1111/cts.70488

BibTeX
@article{Smith2026,
  author = {Smith, Nicholas M and Ho, Brian M and Bar, Katharine J and Gama, Lucio and Dziubla, Gabrielle and Koup, Richard A and Pensiero, Michael and Serebryannyy, Leonid and Caskey, Marina and Wilkin, Timothy J and Wood, Troy D and Morse, Gene D and Venuto, Charles S and Cha, Ray and Ma, Qing},
  title = {Enhanced Clearance of HIV ‐1 Broadly Neutralizing Antibody VRC07 ‐523‐ LS During Viremia: Influences on Trial Design and Analysis},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70488}
}
Kostenlos starten →